23
September 2024
Argent BioPharma
Ltd.
(Argent BioPharma or the Company)
Delisting
Update
Argent BioPharma, an innovative
multidisciplinary drug discovery company within the
biopharmaceutical sector, provides the following update regarding
its proposed delisting from the Australian Securities Exchange
(ASX).
The Company wishes to remind
shareholders that it will be holding a shareholder vote
at 4:00 PM (AWST) on Tuesday, 1 October 2024, at
Suite 1, 295 Rokeby Road, Subiaco WA 6008 to allow shareholders to
vote (amongst other things) on its proposed
delisting from the ASX. Any proposed delisting from the ASX is
conditional on, amongst other things, shareholder
approval.
To remain eligible to be listed on
the London Stock Exchange's Main Market and the Financial Conduct
Authority's (FCA) Official
List in the event of a delisting from the ASX, application must be
made to, and approved by, the FCA to transfer the Company's listing
category on the Official List in accordance with the UK Listing
Rules (Application). The
Company is currently listed on the equity shares (international
commercial companies secondary listing) category of the FCA's
Official List, but prior to any delisting from ASX, the Company
intends to apply to move its listing to the equity shares
(commercial companies) category (ESCC) of the FCA's Official List. There
are a number of prerequisites and eligibility requirements that
will need to be met for an Application to be approved, one being
the appointment of a Sponsor, and following any such transfer the
Company would be subject to additional disclosure and corporate
governance obligations. There can be no guarantee whether or when
an Application to transfer listing category will be approved, in
which case there is no guarantee that the Company will delist from
the ASX, notwithstanding whether shareholder approval is given. The
Company will not delist from the ASX without such approval of the
Application to transfer to the ESCC.
-Ends-
Authorised for release by the board of directors, for further
information please contact:
About Argent
BioPharma
Argent BioPharma Limited (the
"Company") (ASX: RGT; LSE:
RGT; OTCQB: RGTLF) an innovative multidisciplinary drug development
Company within the biopharmaceutical sector. The Company
focuses on multidisciplinary methods with Nanotechnology,
developing multi-target therapies for comprehensive disease
management, especially concerning the central nervous system
("CNS") and Immunology treatments.
Follow us through our social media
channels:
LinkedIn: Argent
BioPharma
Twitter: @ArgentBioPharma
Facebook: Argent
BioPharma
